StockWorld News

Merck CEO on upbeat guidance: ‘our COVID pill will make a meaningful difference’

Merck CEO on upbeat guidance: ‘our COVID pill will make a difference’

Ad disclosure

Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >

By:

Wajeeh Khan

on
Oct 28, 2021

Merck gives upbeat guidance for the full year after beating estimates in Q3.

CEO Davis discussed earnings and future prospects on CNBC’s “Squawk Box”.

Shares of the pharmaceutical company were up 2.0% in premarket trading.

Merck & Co Inc (NYSE: MRK) reported its financial results for the third quarter on Thursday that beat Wall Street estimates. Shares of the pharmaceutical company were up 2.0% in premarket trading on upbeat guidance for the full year.

Highlights from CEO Davis’ interview with CNBC’s ‘Squawk Box’

On CNBC’s “Squawk Box”, CEO Robert Davis agreed that the pandemic situation was improving but reiterated that he saw opportunity in Merck’s COVID-19 pill.


Are you looking for fast-news, hot-tips and market analysis?

Sign-up for the Invezz newsletter, today.

While some of the numbers around COVID-19 are improving, it’s still having a grievous impact globally. So, we believe that our antiviral drug will make a meaningful difference. We’re working with the FDA to get the approval as quickly as possible.

The FDA advisory committee is scheduled to meet in late November to decide on Merck’s COVID-19 pill. Upon approval, Davis disclosed, Merck is in a position to deliver 10 million courses of the oral drug by the end of 2021 and over 20 million next year.

Full-year guidance

For fiscal 2021, Merck forecasts up to $5.70 of adjusted EPS on $47.4 billion to $47.9 billion in revenue, as per the earnings press release.

In comparison, analysts are calling for $5.63 of adjusted per-share earnings on $47.60 billion in sales.

Q3 financial performance

Merck said its net income printed at $4.57 billion that translates to $1.80 per share. In the same quarter last year, its net income was capped at $2.94 billion or $1.16 per share. Adjusted for one-time items, the drugmaker earned $1.75 a share.

The American multinational generated $13.15 billion in sales that represents an annualised growth of 20.4%. According to FactSet, experts had forecast $1.55 of adjusted EPS on $12.32 billion in sales.

Merck saw a sharp recovery in all of its businesses, with pharmaceutical sales up 18.3%, Keytruda sales up 22%, animal health sales up 16.1%, and the vaccine business up 68% in Q3.

Invest in crypto, stocks, ETFs & more in minutes with our preferred broker,

eToro

10/10

67% of retail CFD accounts lose money

Visit site

Health & pharmaceuticals

Industries

North America

Stocks & Shares

USA

World